BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31217905)

  • 1. 1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours.
    Butler CT; Kennedy SA; Buckley A; Doyle R; Conroy E; Gallagher WM; O'Sullivan J; Kennedy BN
    Oncotarget; 2019 Jun; 10(38):3725-3744. PubMed ID: 31217905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
    Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
    J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.
    Murphy AG; Casey R; Maguire A; Tosetto M; Butler CT; Conroy E; Reynolds AL; Sheahan K; O'Donoghue D; Gallagher WM; Fennelly D; Kennedy BN; O'Sullivan J
    Sci Rep; 2016 Oct; 6():34523. PubMed ID: 27739445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors.
    Kennedy SA; Morrissey ME; Dunne MR; O'Connell F; Butler CT; Cathcart MC; Buckley AM; Mehigan BJ; Larkin JO; McCormick P; Kennedy BN; O'Sullivan J
    BMC Cancer; 2020 Oct; 20(1):952. PubMed ID: 33008336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1,4-dihydroxy quininib modulates the secretome of uveal melanoma tumour explants and a marker of oxidative phosphorylation in a metastatic xenograft model.
    Slater K; Bosch R; Smith KF; Jahangir CA; Garcia-Mulero S; Rahman A; O'Connell F; Piulats JM; O'Neill V; Horgan N; Coupland SE; O'Sullivan J; Gallagher WM; Villanueva A; Kennedy BN
    Front Med (Lausanne); 2022; 9():1036322. PubMed ID: 36698840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis.
    Reynolds AL; Alvarez Y; Sasore T; Waghorne N; Butler CT; Kilty C; Smith AJ; McVicar C; Wong VH; Galvin O; Merrigan S; Osman J; Grebnev G; Sjölander A; Stitt AW; Kennedy BN
    J Biol Chem; 2016 Apr; 291(14):7242-55. PubMed ID: 26846851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells.
    Slater K; Heeran AB; Garcia-Mulero S; Kalirai H; Sanz-Pamplona R; Rahman A; Al-Attar N; Helmi M; O'Connell F; Bosch R; Portela A; Villanueva A; Gallagher WM; Jensen LD; Piulats JM; Coupland SE; O'Sullivan J; Kennedy BN
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1,4-dihydroxy quininib activates ferroptosis pathways in metastatic uveal melanoma and reveals a novel prognostic biomarker signature.
    Tonelotto V; Costa-Garcia M; O'Reilly E; Smith KF; Slater K; Dillon ET; Pendino M; Higgins C; Sist P; Bosch R; Passamonti S; Piulats JM; Villanueva A; Tramer F; Vanella L; Carey M; Kennedy BN
    Cell Death Discov; 2024 Feb; 10(1):70. PubMed ID: 38341410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A sustained release formulation of novel quininib-hyaluronan microneedles inhibits angiogenesis and retinal vascular permeability in vivo.
    Galvin O; Srivastava A; Carroll O; Kulkarni R; Dykes S; Vickers S; Dickinson K; Reynolds AL; Kilty C; Redmond G; Jones R; Cheetham S; Pandit A; Kennedy BN
    J Control Release; 2016 Jul; 233():198-207. PubMed ID: 27086168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Development of the Quininib Series of Ocular Drugs.
    Mahon N; Slater K; O'Brien J; Alvarez Y; Reynolds A; Kennedy B
    J Ocul Pharmacol Ther; 2022; 38(1):33-42. PubMed ID: 35089801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
    Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
    J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tumor angiogenesis: new approaches to cancer therapy].
    Marmé D
    Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels.
    Ding C; Luo J; Fan X; Li L; Li S; Wen K; Feng J; Wu G
    J Exp Clin Cancer Res; 2017 Apr; 36(1):56. PubMed ID: 28420432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diallyl trisulfide inhibits migration, invasion and angiogenesis of human colon cancer HT-29 cells and umbilical vein endothelial cells, and suppresses murine xenograft tumour growth.
    Lai KC; Hsu SC; Yang JS; Yu CC; Lein JC; Chung JG
    J Cell Mol Med; 2015 Feb; 19(2):474-84. PubMed ID: 25403643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
    Siemeister G; Schirner M; Weindel K; Reusch P; Menrad A; Marmé D; Martiny-Baron G
    Cancer Res; 1999 Jul; 59(13):3185-91. PubMed ID: 10397264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour-associated angiogenesis in human colorectal cancer.
    Rmali KA; Puntis MC; Jiang WG
    Colorectal Dis; 2007 Jan; 9(1):3-14. PubMed ID: 17181841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.
    Wiegering A; Korb D; Thalheimer A; Kämmerer U; Allmanritter J; Matthes N; Linnebacher M; Schlegel N; Klein I; Ergün S; Germer CT; Otto C
    Neoplasia; 2014 Nov; 16(11):972-81. PubMed ID: 25425971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
    Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
    Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4'-hydroxywogonin inhibits colorectal cancer angiogenesis by disrupting PI3K/AKT signaling.
    Sun D; Zhang F; Qian J; Shen W; Fan H; Tan J; Li L; Xu C; Yang Y; Cheng H
    Chem Biol Interact; 2018 Dec; 296():26-33. PubMed ID: 30217479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.